- Research article
- Open Access
- Open Peer Review
Burden of hospitalizations over time with invasive aspergillosis in the United States, 2004–2013
© The Author(s). 2019
- Received: 7 March 2018
- Accepted: 1 May 2019
- Published: 17 May 2019
Using aggregated data available on the interactive website from the Agency for Healthcare Research and Quality’s Healthcare Cost and Utilization Project Network (HCUPnet), we examined the annual volume of invasive aspergillosis (IA)-related hospitalizations in the US.
This was a population study. Age-adjusted volumes were derived through population incidence calculated using year-specific censal and intercensal US population estimates available from the US Census Bureau. We additionally examined IA as the principal diagnosis and its associated outcomes in patients with ICD-9-CM codes 117.3, 117.9 and 484.6.
The age-adjusted number of annual hospitalizations with IA grew from 35,968 cases in 2004 to 51,870 in 2013, a 44.2% overall increase, 4.4% per annum. Regionally, the South contributed the plurality of the cases (40%), and the Northeast the fewest (17%). While IA as principal diagnosis dropped, from 14.4 to 9.3%, mortality rose from 10 to 12%. Despite mean hospital length of stay decreasing from 13.3 (standard error [SE] 0.07) to 11.5 (SE 0.6) days, the corresponding mean hospital charges rose from $71,164 (SE $5248) to $123,005 (SE $9738). The aggregate US inflation-adjusted hospital charges for IA principal diagnosis rose from $436,074,445 in 2004 to $592,358,369 in 2013.
Given the substantial volume and rate of growth in IA-related hospitalizations in the US between 2004 and 2013, an increase in mortality and high costs, IA may represent an attractive target for intensive preventive efforts.
- Population study
- United States
- Invasive aspergillosis
Invasive aspergillosis (IA) represents a severe infection in many types of patients. It is a growing problem, given the broader use of intensive immunosuppressive regimens for various diseases, increases in organ transplantation and improved diagnostics [1, 2]. Recent US studies described a substantial increase in the prevalence of IA in general, and specifically among patients with hematologic malignancies and those undergoing organ transplants . Despite aggressive prophylaxis in select populations, IA remains associated with high crude and attributable mortality, and by some estimates, the economic costs of IA approach $600 million annually in the US .
Limited data exist, however, describing in detail recent trends in epidemiology and outcomes associated with IA. Hence, we aimed to explore time trends in the prevalence, mortality and hospital resource utilization associated with IA among a diverse cohort of hospitalized patients.
We estimated the annual burden of all IA-related hospitalizations in the US between 2004 and 2013 using similar methods to those published previously [5–15]. The data for this analysis were derived from the HCUPnet, a website for querying aggregate data from the Healthcare Cost and Utilization Project (HCUP), administered by the Agency for Healthcare Research and Quality (AHRQ) . Specifically, we examined the annual incidence of IA-related hospitalizations, based on the presence of the International Classification of Diseases, version 9, Clinical Modification (ICD-9-CM) codes 117.3, 117.9 and 484.6, which were shown to be sensitive in detecting IA . We examined population incidence (reported as cases per 100,000 population) using year-specific censal and intercensal US population estimates available from the US Census Bureau . We additionally examined IA incidence by normalizing it to all hospitalizations within a given year (reported as cases per 10,000 all-cause hospitalizations). Each incidence estimate was stratified by age group and census region in separate analyses.
We also estimated the annual burden of hospitalizations with IA as the principal discharge diagnosis. IA as the principal diagnosis is presented as a proportion of total IA hospitalizations per annum. On the assumption that principal diagnosis implies that the outcomes of the hospitalization could be attributed to IA, we examined unadjusted mortality, length of stay (LOS), costs and charges (both raw and inflation-corrected) in this cohort. To correct costs and charges for inflation, we employed the medical component of the Consumer Price Index available from the US Bureau of Labor Statistics . The variation in these outcomes was assessed using standard error (SE) estimates where available. No formal inferential statistical testing was undertaken.
Annual hospitalizations with a diagnosis of invasive aspergillosis, by region
Incidence per 100,000 population
Incidence per 10,000 all-cause hospitalizations
We confirm an increase in IA cases among hospitalized patients in the decade from 2004 to 2013. The magnitude of growth in the age-adjusted annual volume of IA hospitalizations in the current study (4.4%) echoes that noted within the National Inpatient Sample (NIS) by Vallabhaneni and co-authors (2.9%) . To build on those authors’ work, we examined in detail the changes in IA hospitalizations over time. We stratified the data by such important factors as age and geography, and these stratifications clarify the nuances of the fluctuations in the IA incidence over the time frame of the study, which are smoothed out when looking at the overall population . Despite these fluctuations, however, there was general growth in volume, which neared 50% over the decade examined. Normalizing the annual incidence to all US hospitalizations adds further granularity to understanding the impact of IA over time at the hospital level. Finally, our study adds to the understanding of the hospital resource utilization burden associated with IA.
We further observed that the proportion of IA hospitalizations with IA as the principal diagnosis dropped from 14 to 9% during the study period. Both of these estimates are far below a prior analysis of the NIS, a part of the HCUP, in 1996, in which over one quarter of all IA admissions carried it as the principal diagnosis . Although it is reasonable to assume that most IA requires inpatient treatment, the precipitous and continuing drop in IA as the primary reason for hospitalization we note implies that other maladies are taking precedence over IA in necessitating admissions. In other words, IA may no longer represent the primary driver for hospitalization.
Our finding of a rise in crude mortality from 10 to 12% among patients with IA as the principal diagnosis, if not a cause for concern, at the very least requires further exploration. This is particularly necessary since analyses of the same source have consistently reported the death rate in this subgroup of 14 to 15% [4, 20]. It is likely that the explanation for the increase in mortality that we observed is due to the parallel increase in the severity of underlying illness among groups of patients whose diseases are now treated more aggressively and routinely, resulting in heightened susceptibility to IA. However, this requires confirmation.
We also found that while the IA-associated LOS decreased, the inflation-adjusted charges attributed to it rose by over $20/admission between 2004 and 2013. However, despite this increase in charges, the costs remained stable at approximately $32,000. This disparity between charges and costs may be indicative of a widening gap between expenditures and reimbursement incurred by hospitals over time. Of equal importance, the national bill for hospitalizations with IA as the principal diagnosis nearly doubled from a little over $300 million in 2004 to nearly $600 million in 2013. Not unexpectedly, these charges far exceed those noted in 1996 ($112.5 million) . Notably, in Dasbach and colleagues’ study, patients with IA as the primary diagnosis (27% of all IA patients) contributed approximately 18% of the total aggregate US costs associated with all IA hospitalizations . This implies that, given the 9% prevalence of IA as the principal diagnosis relative to all hospitalizations involving an IA code, and the total national bill for IA as principal diagnosis of approximately $600 million, the aggregate annual US charges for all IA-related hospitalizations in 2013 are likely exceeded $6 billion.
Our findings point to year-to-year and geographic variations in IA hospitalization incidence. Although our data do not allow for examinations of causality, these results point to potential directions for future research to shed light on whether there are modifiable risk factors and preventive strategies that may lessen the burden of IA hospitalizations.
Our study has a number of limitations. We may have overestimated the number of IA cases when all ICD-9-CM codes were added together, as any overlaps in these diagnoses within a single hospitalization cannot be identified in the HCUPnet. Though unavailable to us in the current analysis, in a separate study in this population, we reported the crude 30-day readmission rate to be 18% among survivors of a prior IA hospitalization . Similarly, the annual incidence of IA may also be overestimated, as all cases were counted as first occurrences, when in fact a certain proportion of them may have represented readmissions. Additionally, the HCUPnet data lack the granularity necessary to examine important clinical, demographic and hospital factors that may explain some of our findings. The strength of the current study, however, lies in its vast numbers and broad generalizability to all US institutions.
Invasive aspergillosis is a substantial problem in the US, with an age-adjusted annual growth rate of over 4% between 2004 and 2013. We observed a 2% rise over time in IA-associated mortality. However, in the current dataset we could not confirm whether this is indeed due to confounding by increased illness severity and/or treatment intensity. Therefore, this finding requires further scrutiny. Additionally, there is a widening gap between costs and reimbursements for IA hospitalizations, which may present an increasing strain on hospital resources. Given its high and growing morbidity, mortality and costs, intensive measures to prevent IA remain a necessity.
The authors acknowledge Gill Sperrin, CBiol, MRSB, CMPP, of Envision Scientific Solutions, for editorial support.
RH was supported by NCI training grant 5R25-CA057699.
MDZ, RH, JS and AFS contributed substantially to the study design, data interpretation, and the writing of the manuscript. Noone other than the listed authors participated in the study design, analysis, interpretation or manuscript drafting. All authors have read and approved the manuscript.
Rachel Harrington was affiliated to Astellas Pharma Global Development, Inc., Northbrook, IL, USA at the time of the study.
Ethics approval and consent to participate
The data used in this study are all de-identified and publicly available, obviating the requirement for an ethics committee evaluation.
Consent for publication
MDZ reports grants from EviMed Research Group, LLC and Astellas Pharma Inc., during the conduct of the study, personal fees from Paratek, Tetraphase, Melinta, Achaogen, Pfizer, Shionogi, and Cleveland Clinic, grants from Merck and The Medicines Company, and stock ownership from Johnson & Johnson, outside the submitted work; RH was an employee of Astellas Pharma Global Development, Inc. at the time of study and is currently supported by NCI training grant 5R25-CA057699; JS is an employee of Astellas Pharma Global Development, Inc.; AFS has received consultancy fees, research support, and speaker honoraria from Astellas and Merck, and consultancy fees from Cidara.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Health Resources and Services Administration, U.S. Department of Health & Human Services. Organ procurement and transplantation network: view data reports. Available from: https://optn.transplant.hrsa.gov/data/view-data-reports/. [accessed: 14 May 2017].
- Hope WW, Walsh TJ, Denning DW. Laboratory diagnosis of invasive aspergillosis. Lancet Infect Dis. 2005;5:609–22.View ArticleGoogle Scholar
- Vallabhaneni S, Benedict K, Derado G, Mody RK. Trends in hospitalizations related to invasive aspergillosis and mucormycosis in the United States, 2000–2013. Open Forum Infect Dis. 2017;4:ofw268. https://doi.org/10.1093/ofid/ofw268.View ArticlePubMedPubMed CentralGoogle Scholar
- Dasbach EJ, Davies GM, Teutsch SM. Burden of aspergillosis-related hospitalizations in the United States. Clin Infect Dis. 2000;31:1524–8.View ArticleGoogle Scholar
- Zilberberg MD, de Wit M, Pirone JR, Shorr AF. Growth in adult prolonged acute mechanical ventilation: implications for healthcare delivery. Crit Care Med. 2008;36:1451–5.View ArticleGoogle Scholar
- Zilberberg MD, Shorr AF, Kollef MH. Increase in adult Clostridium difficile-related hospitalizations and case-fatality rate, United States, 2000–2005. Emerg Infect Dis. 2008;14:929–31.View ArticleGoogle Scholar
- Zilberberg MD, Shorr AF, Kollef MH. Increase in Clostridium difficile-related hospitalizations among infants in the United States, 2000–2005. Pediatr Infect Dis J. 2008;27:1111–3.View ArticleGoogle Scholar
- Zilberberg MD. Assessment of reporting bias for Clostridium difficile hospitalizations, United States. Emerg Infect Dis. 2008;14:1334.View ArticleGoogle Scholar
- Zilberberg MD, Shorr AF, Kollef MH. Secular trends in candidemia-related hospitalization in the United States, 2000–2005. Infect Control Hosp Epidemiol. 2008;29:978–80.View ArticleGoogle Scholar
- Zilberberg MD, Shorr AF, Kollef MH. Growth in the incidence of hospitalizations with resistant infections in elderly people in the United States: 2000 to 2006. J Am Geriatr Soc. 2008;56:2356–8.View ArticleGoogle Scholar
- Zilberberg MD, Shorr AF, Kollef MH. Growth and geographic variation in hospitalizations with resistant infections, United States, 2000–2005. Emerg Infect Dis. 2008;14:1756–8.View ArticleGoogle Scholar
- Zilberberg MD. Clostridium difficile-related hospitalizations among US adults, 2006. Emerg Infect Dis. 2009;15:122–4.View ArticleGoogle Scholar
- Ramsey A, Zilberberg MD. Secular trends of hospitalization with vancomycin-resistant Enterococcus in the United States, 2000-2006. Infect Control Hosp Epidemiol. 2009;30:184–6.View ArticleGoogle Scholar
- Zilberberg MD, Shorr AF. Prolonged acute mechanical ventilation and hospital bed utilization in 2020 in the United States: implications for budgets, plant and personnel planning. BMC Health Serv Res. 2008;8:242.View ArticleGoogle Scholar
- Zilberberg MD, Tillotson GS, McDonald LC. Clostridium difficile infections among hospitalized children, United States, 1997–2006. Emerg Infect Dis. 2010;16:604–9.View ArticleGoogle Scholar
- HCUPnet. Available from: https://hcupnet.ahrq.gov/#setup. [accessed: 6 Dec 2017].
- Chang DC, Burwell LA, Lyon GM, Pappas PG, Chiller TM, Wannemuehler KA, Fridkin SK, Park BJ. Comparison of the use of administrative data and an active system for surveillance of invasive aspergillosis. Infect Control Hosp Epidemiol. 2008;29:25–30.View ArticleGoogle Scholar
- US Census Bureau. Available at http://www.census.gov/. [accessed: 17 Dec 2016].
- The US Bureau of Labor Statistics. Consumer Price Index. Available from: http://www.bls.gov/data/#calculators. [accessed: 6 Dec 2017].
- Zilberberg MD, Nathanson BH, Harrington R, Spalding JR, Shorr AF. Epidemiology and outcomes of hospitalizations with invasive aspergillosis in the United States, 2009–2013. Clin Infect Dis. 2018;67(5):727–35. https://doi.org/10.1093/cid/ciy181.View ArticlePubMedGoogle Scholar